Interferon
Interferons are a family of cytokines with central roles in innate and adaptive immunity, especially in antiviral defense, immune regulation, and tumor surveillance.
Interferons are a family of cytokines with central roles in innate and adaptive immunity, especially in antiviral defense, immune regulation, and tumor surveillance. They are commonly grouped into type I interferons, type II interferon, and type III interferons, with interferon-γ (IFN-γ) being the best-known type II member. Interferon signaling induces broad transcriptional programs that can enhance antigen presentation, activate cytotoxic lymphocytes and macrophages, and shape inflammatory responses through pathways such as JAK-STAT.
Clinically, interferons have long been studied as therapeutic agents and as biomarkers of immune activation or dysregulation. Their effects are context dependent: they can support host defense against viruses and intracellular pathogens, but excessive, prolonged, or misdirected interferon activity can also contribute to tissue inflammation, immune exhaustion, and pathological remodeling in diseases such as COVID-19, cancer, autoimmune disorders, and hemophagocytic syndromes. In recent biomedical research, interferon pathways are frequently examined alongside checkpoint inhibitor therapy, PD-1/PD-L1 blockade, STING1 activation, cGAS-STING pathway signaling, and cytokine-based immunomodulation.
Where the papers sit
17 papers from the last 6 months study interferon directly · updated from PubMed 8 Oct 2026
Study type 0 clinical trials · 2 observational · 2 human data · 12 preclinical · 1 unclassified
Themes no clear themes · 1 paradigm shift · 1 new direction
Those 17 do not share a common subject.
-
IFN-linked immune activation appears across cancer, transplantation, vaccination, infection, and inflammatory disease, but the topics do not converge on one biological question. Individual studies address nanoparticle delivery of IFNα, JAK-STAT-IFN rejection signals, macrophage and T-cell control of tumors, vaccine reactogenicity, and cytokine blockade in hemophagocytic lymphohistiocytosis. The recurring connection is immune modulation rather than a shared mechanism or endpoint. No common therapeutic direction is supported.
Interferon signaling can drive tumor growth and immunotherapy resistance rather than protective antitumor immunity
The melanoma study found that chronic type II interferon activated a mitochondrial RNA–type I interferon–PGE2 pathway that promoted tumor growth and anti-PD-1 resistance, while the cancer-immunotherapy neutrophil study found that IFN-γ induced neutrophil PD-L1 and converted neutrophils into suppressors of treatment response. Together, these independent models show that interferon is not intrinsically antitumor: sustained or context-specific signaling can establish immunosuppressive programs that defeat therapy, making interruption of downstream interferon-associated pathways a therapeutic objective 42721225Sep 42296966Jun.
Interferon signaling is a determinant of mRNA-vaccine reactogenicity
The mRNA-vaccine reactogenicity study identified baseline monocyte interferon signaling and early, locally initiated interferon production as contributors to systemic postvaccination symptoms, alongside antibody-mediated innate activation. This assigns interferon a role not used elsewhere in the set—as a mechanistic source of variability in vaccine tolerability, rather than principally an antitumor effector, rejection marker, infection therapy, or disease-pathology pathway 42647597Aug.
Papers
The 17 papers from the last 6 months that study interferon directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
No clear themes (17)
- Synthesis and Optimization of PEG-PLGA Immunotherapeutic Nanoparticles for the Controlled Release of IFNα. AAPS PharmSciTech · 29 Sept 2026 PMID 42811238
- Chronic type II interferon promotes tumor growth through mitochondrial RNA-induced type I interferon and prostaglandin synthesis. Science (New York, N.Y.) · 10 Sept 2026 PMID 42721225
- Oral Milk-Derived Extracellular Vesicles: A Promising Drug Delivery System for Neuroinflammatory Diseases. ACS biomaterials science & engineering · 3 Sept 2026 PMID 42690904
- Baseline interferon signaling in monocytes and antibody-mediated innate activation are associated with reactogenicity to mRNA vaccines. Science translational medicine · 26 Aug 2026 PMID 42647597
- Early versus late JAK-STAT-IFN signaling distinguishes no rejection from subclinical to clinical TCMR after liver transplantation. Science translational medicine · 5 Aug 2026 PMID 42555758
- Context-Dependent Cancer Vulnerabilities: CRISPR Screening under Inflammatory Stress. Cancer research · 24 Jul 2026 PMID 42496673
- Cooperative IFN-γ and TLR9 signaling reprogram tumor-associated macrophages to enhance antitumor immunity in melanoma. Biochemical and biophysical research communications · 22 Jul 2026 PMID 42485794
- Dendritic cells control tertiary lymphoid structure development and maintenance in cancer. Science (New York, N.Y.) · 16 Jul 2026 PMID 42462020
- T cell-associated immunity induced by heterologous recombinant BCG and purified protein vaccination confers cross-variant protection against SARS-CoV-2. Human vaccines & immunotherapeutics · 9 Jul 2026 PMID 42423335
- Emapalumab plus conventional therapy with or without ruxolitinib for pediatric hemophagocytic lymphohistiocytosis: a single center retrospective study. Immunologic research · 3 Jul 2026 PMID 42397658
- Real-world impact of national policy on high-efficacy therapy use in multiple sclerosis: A Brazilian big data analysis. Multiple sclerosis and related disorders · 27 Jun 2026 PMID 42364568
- Treg cells promote immunotherapy-induced immune evasion by restraining CD4 T cell control of MHC-I-deficient metastatic pancreatic cancer. Science immunology · 26 Jun 2026 PMID 42361199
- Neutrophil regulation of immunotherapy for cancer is controlled by type II interferon. Immunity · 15 Jun 2026 PMID 42296966
- Emerging evidence for anti-PD-1 and IFN-γ as adjunctive immunotherapy in invasive mold infections. mBio · 22 May 2026 PMID 42171361
- A high dimensionality approach reveals immunopathogenic responses driving severe pediatric acute respiratory distress syndrome. Nature communications · 15 May 2026 PMID 42140972
- Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. Cancer cell · 8 May 2026 PMID 42102812
- Single-cell spatial analysis stratifies lung adenocarcinoma with rare actionable mutations and reveals immune-modulatory cellular crosstalk. Cell reports. Medicine · 21 Apr 2026 PMID 42013848
By study type
Observational studies and case reports (2)
- Emapalumab plus conventional therapy with or without ruxolitinib for pediatric hemophagocytic lymphohistiocytosis: a single center retrospective study. Immunologic research · 3 Jul 2026 PMID 42397658
- Real-world impact of national policy on high-efficacy therapy use in multiple sclerosis: A Brazilian big data analysis. Multiple sclerosis and related disorders · 27 Jun 2026 PMID 42364568
Human data, design not indexed (2)
- Synthesis and Optimization of PEG-PLGA Immunotherapeutic Nanoparticles for the Controlled Release of IFNα. AAPS PharmSciTech · 29 Sept 2026 PMID 42811238
- Emerging evidence for anti-PD-1 and IFN-γ as adjunctive immunotherapy in invasive mold infections. mBio · 22 May 2026 PMID 42171361
Preclinical: animal, cell and lab studies (12)
- Chronic type II interferon promotes tumor growth through mitochondrial RNA-induced type I interferon and prostaglandin synthesis. Science (New York, N.Y.) · 10 Sept 2026 PMID 42721225
- Oral Milk-Derived Extracellular Vesicles: A Promising Drug Delivery System for Neuroinflammatory Diseases. ACS biomaterials science & engineering · 3 Sept 2026 PMID 42690904
- Baseline interferon signaling in monocytes and antibody-mediated innate activation are associated with reactogenicity to mRNA vaccines. Science translational medicine · 26 Aug 2026 PMID 42647597
- Early versus late JAK-STAT-IFN signaling distinguishes no rejection from subclinical to clinical TCMR after liver transplantation. Science translational medicine · 5 Aug 2026 PMID 42555758
- Context-Dependent Cancer Vulnerabilities: CRISPR Screening under Inflammatory Stress. Cancer research · 24 Jul 2026 PMID 42496673
- Cooperative IFN-γ and TLR9 signaling reprogram tumor-associated macrophages to enhance antitumor immunity in melanoma. Biochemical and biophysical research communications · 22 Jul 2026 PMID 42485794
- Dendritic cells control tertiary lymphoid structure development and maintenance in cancer. Science (New York, N.Y.) · 16 Jul 2026 PMID 42462020
- T cell-associated immunity induced by heterologous recombinant BCG and purified protein vaccination confers cross-variant protection against SARS-CoV-2. Human vaccines & immunotherapeutics · 9 Jul 2026 PMID 42423335
- Treg cells promote immunotherapy-induced immune evasion by restraining CD4 T cell control of MHC-I-deficient metastatic pancreatic cancer. Science immunology · 26 Jun 2026 PMID 42361199
- Neutrophil regulation of immunotherapy for cancer is controlled by type II interferon. Immunity · 15 Jun 2026 PMID 42296966
- Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. Cancer cell · 8 May 2026 PMID 42102812
- Single-cell spatial analysis stratifies lung adenocarcinoma with rare actionable mutations and reveals immune-modulatory cellular crosstalk. Cell reports. Medicine · 21 Apr 2026 PMID 42013848
Unclassified: not yet indexed with MeSH (1)
- A high dimensionality approach reveals immunopathogenic responses driving severe pediatric acute respiratory distress syndrome. Nature communications · 15 May 2026 PMID 42140972
Written from 17 PubMed abstracts, each one listed by PMID above. Published: 2026-07-10. Last written: 2026-09-12 by GPT. Drafted by language models from published abstracts; not medical advice.